A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (ALARMONY)
ALARMONY: A Phase 2 Randomized, Double Blind, Placebo Controlled Multi-center Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe COPD
This study is for adult participants with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who continue to experience exacerbations despite standard of care triple therapy treatment. It will assess the effectiveness and safety of two investigational drugs, GSK3862995B and GSK5784283, given together compared to a placebo in addition to standard of care.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 2
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Studijní záloha kontaktů
- Jméno: EU GSK Clinical Trials Call Center
- Telefonní číslo: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Studijní místa
-
-
-
Bradford, Spojené království, BD9 6RJ
- Nábor
- GSK Investigational Site
-
Vrchní vyšetřovatel:
- Dinesh Saralaya
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
London, Spojené království
- Nábor
- GSK Investigational Site
-
Vrchní vyšetřovatel:
- Brian Leaker
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
California
-
Newport Beach, California, Spojené státy, 92663
- Nábor
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Vrchní vyšetřovatel:
- Ryan Klein
-
-
Florida
-
Miami, Florida, Spojené státy, 33176-7016
- Nábor
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Vrchní vyšetřovatel:
- Andrew Pastewski
-
-
Kansas
-
Derby, Kansas, Spojené státy, 67037
- Nábor
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Vrchní vyšetřovatel:
- Scott Meyers
-
-
Maryland
-
Columbia, Maryland, Spojené státy, 21045
- Nábor
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Vrchní vyšetřovatel:
- David Nyanjom
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73111
- Nábor
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Vrchní vyšetřovatel:
- Charles Lunn
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- Nábor
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Vrchní vyšetřovatel:
- David Wheeler
-
-
South Carolina
-
Rock Hill, South Carolina, Spojené státy, 29732
- Nábor
- GSK Investigational Site
-
Vrchní vyšetřovatel:
- Michael Denenberg
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
Texas
-
Tomball, Texas, Spojené státy, 77375
- Nábor
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Vrchní vyšetřovatel:
- Amanbir Sohal
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Participants must be greater than or equal to (>=) 40 to less than or equal to (<=) 80 years of age, at the time of signing the informed consent
-
Basal Metabolic Rate (BMI) >= 16 kilogram per meter square (kg/m^2)
-
Moderate to severe COPD with frequent exacerbations, defined as
- a clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year prior to the screening visit;
- a post-salbutamol FEV1/Forced vital capacity (FVC) ratio of less than (<) 0.70 and a post-salbutamol FEV1 greater than (>) 30 percent (%) and >= 80% predicted normal values calculated withGlobal Lung Function Initiative (GLI) - Global Race Neutral equations in line with the American Thoracic Society (ATS) recommendations at screening;
- a well-documented history (e.g., medical record verification, including capturing of all prior biologic use) of at least 2 moderate or 1 severe exacerbations in the 12 months prior to screening despite the use of Inhaled Corticosteroids (ICS) containing maintenance COPD treatment; at least one qualifying exacerbation must have occurred while participant was on ICS plus long-acting muscarinic antagonist (LAMA) plus long-acting beta agonist (LABA); Moderate exacerbations must have been treated with systemic corticosteroids and/or antibiotics (subcutaneous [SCS]; Intramuscular [IM], Intravenous [IV], or oral); Severe exacerbations are those requiring hospitalization or observation >24 hours in the emergency department /urgent care facility
-
Smoking status: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at Screening. Former smokers are defined as those who have stopped all cigarette smoking for at least 6 months prior to the Screening Visit
-
An eosinophilic phenotype with elevated Blood eosinophil count (BEC) at screening
-
CAT total score ≥ 10,
-
Participants should be on standard of care COPD maintenance inhaler therapy, defined as ICS plus LAMA plus LABA either as multiple inhalers or a single combination inhaler for at least 6 months prior to the Screening Visit and on a stable dose for at least 3 months prior to the Screening Visit
-
Participants on adjunctive COPD therapies such as chronic macrolide antibiotics, Phosphodiesterase (PDE)4 or PDE3-4 inhibitors, or chronic oral corticosteroids (up to 15 mg prednisone equivalent per day) may participate, provided they have been on these medications for 6 months, and on a stable dose for at least 3 months immediately prior to the Screening Visit
-
A female participant is eligible to participate if she is not pregnant or breastfeeding
-
Is a Participant of non-childbearing potential (PONCBP)
-
Is a Participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective, with a failure rate of <1%, at least 42 days prior to and during the study intervention period and for at least 60 weeks after the last dose of study intervention.
-
Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol
Exclusion Criteria:
- Participants with a current or prior physician diagnosis of asthma are excluded
- Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease. Participants with α1-antitrypsin deficiency as the underlying cause of COPD are excluded. Also excluded are participants with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
- COPD stability: Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening are excluded
- Lung resection: Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure are excluded
- Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to the Screening Visit are excluded. Participants who are in the maintenance phase of a pulmonary rehabilitation program may participate
- Continuous oxygen: Participants requiring oxygen supplementation for more than 12 hours per day are excluded. Non-continuous (i.e., 12 hours or less per day) oxygen is permitted up to 2 Liters per minute (L/min) at the time of the screening visit and for the duration of the study. Participants on long term oxygen therapy (LTOT) should be ambulatory and able to attend clinic visits
- Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension is excluded
- Chronic hypercapnia requiring Non-invasive Positive Pressure Ventilation (NIPPV) use (including Bilevel Positive Airway Pressure [BiPAP] or Continuous positive airway pressure [CPAP]) are excluded
- Participants with unstable cardiac disease; myocardial infarction or stroke within 12 months prior to screening; or New York Heart Association Class III or IV heart failure
- Participants with clinically significant abnormal Electrocardiogram (ECG) at screening which in the judgment of the Investigator, may affect participant safety or affect study endpoints
- Participants with a history of lymphoma, leukemia, or any malignancy within the past 5 years, except for basal cell or squamous epithelial carcinomas of the skin that have been resected for cure with no evidence of recurrence or metastatic disease for 1-year
- A known or suspected immunodeficiency that has led to opportunistic infections, recurrent invasive infections, or prolonged infections that suggest an underlying immunocompromised state by the judgement of the investigator. Positive HIV antibody test
- Active Nontuberculous mycobacterial (NTM) lung infection on treatment or meeting ATS/ Infectious Diseases Society of America (IDSA) criteria for active lung infection
- Active tuberculosis, untreated latent Tuberculosis (TB), invasive fungal lung infections or allergic bronchopulmonary aspergillosis needing treatment
- Participants should not have an active, invasive fungal infection as assessed by the investigator and should not be on chronic antifungal therapy. Participants who have completed antifungal therapy more than 4 weeks prior to screening and have been deemed clinically cured are eligible
- Vasculitis: Participants with current diagnosis of vasculitis. Participants with high clinical suspicion of vasculitis at screening will be evaluated and current vasculitis must be excluded prior to enrolment
- Eosinophilic disease: Participants with other conditions that could lead to elevated eosinophils such as Hypereosinophilic syndromes including Eosinophilic Granulomatosis with Polyangiitis (EGPA) (also known as Churg-Strauss Syndrome), or Eosinophilic Esophagitis
- Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening, or infection detected at Screening
- History of an unresolved clinically significant infection within 30 days prior to the screening visit
- Immunodeficiency: A known immunodeficiency other than that explained by use of corticosteroids (e.g., HIV)
- Other concurrent medical conditions: Participants with (historical or) current evidence of clinically significant, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Clinically significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the participant at risk through participation, or which could affect the efficacy or safety analysis if the disease/condition exacerbated during the study
- A positive human immunodeficiency virus (HIV) test at screening or subject taking antiretroviral medications, as determined by medical history and/or subject's verbal report
- Presence of hepatitis B surface antigen (HBsAg) and/or hepatitis B virus (HBV) DNA at screening or within 3 months prior to first dose of study intervention. HBV DNA will only be tested if a participant is core antibody positive
- Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
- Alanine aminotransferase (ALT) >2*Upper Limit to Normal (ULN)
- Total bilirubin >1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5xULN as long as direct bilirubin is <=1.5*ULN
- Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice
- Previous documented treatment failure or non-response to anti-IL-33 or anti - Thymic Stromal Lymphopoietin (TSLP) therapy
- Short term oral corticosteroids: Participants who have received short term use of oral corticosteroids within 4 weeks of the Screening Visit
- Use of immunosuppressive medication (e.g., methotrexate, mycophenolate, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid, maintenance systemic (oral) corticosteroids for an indication other than COPD) within 3 months prior to screening and up until the end of the study treatment period (i.e., Week 24-72 depending on whether the participant is scheduled to receive 2-6 doses of the study intervention)
- Received any live attenuated vaccine within 30 days prior to screening or plans to receive such vaccines up until the end of the study
- Ongoing treatment with cyclic doses of systemic antibiotics
- Current enrollment or past participation in another investigational study in which an investigational intervention (e.g., drug, vaccine, invasive device) was administered within the following time period prior to the screening visit of the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). This also includes investigational formulations of a marketed product
- Previously participated in any clinical study with biologic treatments for respiratory conditions (e.g., omalizumab, mepolizumab, dupilumab, reslizumab, benralizumab, tezepelumab or depemokimab) and received study intervention (including placebo) within 12 months prior to Screening
- Receipt of any investigational non-biologic agent within 1 month or 5 half-lives prior to screening, whichever is longer and up until the end of the follow-up period
- Experimental vaccines are not permitted within 30 days prior to randomization and up until the end of the follow-up period
- Previous randomization in the present study
- Known or suspected history of alcohol or drug abuse with 2 years prior to screening
- History of severe allergic reaction, anaphylaxis or documented immune complex disease (Type III hypersensitivity reactions) to any biologic therapy
- Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: GSK3862995B co-administered with GSK5784283
Participants will receive co-administration of GSK3862995B and GSK5784283 in addition to their standard of care (SoC) triple therapy for COPD. |
Participants will receive GSK3862995B. Participants will receive GSK5784283. |
|
Komparátor placeba: Placebo
Participants will receive a matching placebo in addition to their SoC triple therapy for COPD. |
Participants will receive matching Placebo. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Annualized Rate of Moderate/severe Exacerbations in Former Smokers
Časové okno: Up to 72 weeks
|
A moderate exacerbation is defined as a clinically significant exacerbation that requires treatment with oral/systemic corticosteroids and/or antibiotics. A severe exacerbation is defined as a clinically significant exacerbation that that requires in-patient hospitalization or results in death. The annualized rate will be derived using exacerbations data collected during the study for former smokers. |
Up to 72 weeks
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants with Serious Adverse Events and Adverse Events in All Comers (Former and Current smokers) with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Časové okno: Up to 120 weeks
|
Up to 120 weeks
|
|
|
Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters, Vital Signs, and 12-Lead Electrocardiogram (ECG) in All Comers (Former and Current smokers) with Moderate to Severe COPD
Časové okno: Up to 120 weeks
|
Up to 120 weeks
|
|
|
Time to First Exacerbation in Former Smokers with Moderate to Severe COPD
Časové okno: Up to 72 weeks
|
Up to 72 weeks
|
|
|
Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) at Week 24 in Former Smokers with Moderate to Severe COPD
Časové okno: Baseline and Week 24
|
Baseline and Week 24
|
|
|
Change from Baseline in SGRQ-C total score at Week 24 in Former Smokers with Moderate and Severe COPD
Časové okno: Baseline and Week 24
|
The SGRQ C is a validated, disease specific patient reported outcome instrument used to assess health related quality of life in patients with chronic obstructive pulmonary disease (COPD), capturing the impact of respiratory symptoms, activity limitations, and psychosocial effects of the disease. It calculates domain scores (Symptoms, Activity, and Impacts) and an overall Total Score based on weighted responses to approximately 40 questionnaire items, which yield to a score ranges from 0 (no impairment; best health status) to 100 (maximum impairment; worst health status). |
Baseline and Week 24
|
|
Change from baseline in the COPD Assessment Test (CAT) Score at Week 24 in Former Smokers with Moderate to Severe Smokers
Časové okno: Baseline and Week 24
|
The CAT is a short, patient-completed questionnaire developed to measure the health status of individuals with Chronic Obstructive Pulmonary Disease (COPD). The CAT consists of 8 items, and for each item, the participant provides a rating on a 6-point scale from 0 (representing no impairment) to 5 (representing maximum impairment). A total score is derived by summing the scores of the 8 items, resulting in a scoring range of 0 to 40. Higher scores indicate a greater impact of the disease on the participants health. |
Baseline and Week 24
|
|
Change from baseline in the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) score at Week 24 in Former Smokers with Moderate to Severe COPD
Časové okno: Baseline and Week 24
|
The E-RS: COPD is a patient-reported outcome diary developed to measure the severity of respiratory symptoms in patients with stable COPD. It consists of 11 respiratory symptom items from the 14-item EXAcerbations of Chronic pulmonary disease Tool (EXACT). Participants complete the diary each evening, rating their symptoms for that day. The E-RS: COPD total score is calculated by summing the responses to the 11 items, with a scoring range of 0 to 40. Higher scores indicate more severe respiratory symptoms. The instrument also includes three subscales: Breathlessness (5 items; score range 0-17), Cough and Sputum (3 items; score range 0-11), and Chest Symptoms (3 items; score range 0-12). The E-RS: COPD is designed to capture symptoms such as breathlessness, cough, sputum production, chest congestion, and chest tightness. |
Baseline and Week 24
|
|
Annualized rate of Moderate/Severe Exacerbations in all Comers (Former and Current smokers)
Časové okno: Up to 72 weeks
|
A moderate exacerbation is defined as a clinically significant exacerbation that requires treatment with oral/systemic corticosteroids and/or antibiotics. A severe exacerbation is defined as a clinically significant exacerbation that that requires in-patient hospitalization or results in death. The annualized rate will be derived using exacerbations data collected during the study for former smokers. |
Up to 72 weeks
|
|
Time to First Exacerbation in all Comers (Former and current Smokers) with Moderate to Severe COPD
Časové okno: Up to 72 weeks
|
Up to 72 weeks
|
|
|
Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) at Week 24 in all comers (Former and Current Smokers) with Moderate to Severe COPD
Časové okno: Baseline and Week 24
|
Baseline and Week 24
|
|
|
Change from Baseline in SGRQ-C total score at Week 24 in all Comers (Former and Current Smokers) with Moderate and Severe COPD
Časové okno: Baseline and Week 24
|
The SGRQ C is a validated, disease specific patient reported outcome instrument used to assess health related quality of life in patients with chronic obstructive pulmonary disease (COPD), capturing the impact of respiratory symptoms, activity limitations, and psychosocial effects of the disease. It calculates domain scores (Symptoms, Activity, and Impacts) and an overall Total Score based on weighted responses to approximately 40 questionnaire items, which yield to a score ranges from 0 (no impairment; best health status) to 100 (maximum impairment; worst health status). |
Baseline and Week 24
|
|
Change from baseline in the CAT Score at Week 24 all Comers (Former and Current Smokers) with Moderate to Severe Smokers
Časové okno: Baseline and Week 24
|
The CAT is a short, patient-completed questionnaire developed to measure the health status of individuals with Chronic Obstructive Pulmonary Disease (COPD). The CAT consists of 8 items, and for each item, the participant provides a rating on a 6-point scale from 0 (representing no impairment) to 5 (representing maximum impairment). A total score is derived by summing the scores of the 8 items, resulting in a scoring range of 0 to 40. Higher scores indicate a greater impact of the disease on the participants health. |
Baseline and Week 24
|
|
Change from baseline in the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) score at Week 24 in all comers (Former and current Smokers) with Moderate to Severe COPD
Časové okno: Baseline and Week 24
|
The E-RS: COPD is a patient-reported outcome diary developed to measure the severity of respiratory symptoms in patients with stable COPD. It consists of 11 respiratory symptom items from the 14-item EXAcerbations of Chronic pulmonary disease Tool (EXACT). Participants complete the diary each evening, rating their symptoms for that day. The E-RS: COPD total score is calculated by summing the responses to the 11 items, with a scoring range of 0 to 40. Higher scores indicate more severe respiratory symptoms. The instrument also includes three subscales: Breathlessness (5 items; score range 0-17), Cough and Sputum (3 items; score range 0-11), and Chest Symptoms (3 items; score range 0-12). The E-RS: COPD is designed to capture symptoms such as breathlessness, cough, sputum production, chest congestion, and chest tightness. |
Baseline and Week 24
|
|
Serum concentrations of GSK3862995B and GSK5784283 in all comers (former and current smokers) with moderate to severe COPD
Časové okno: Week 2; pre-dose on Weeks 12, 24, 36, 48, 60; and Week 72
|
Week 2; pre-dose on Weeks 12, 24, 36, 48, 60; and Week 72
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- 224014
- 2026-526506-33 (Jiný identifikátor: EU CT Number)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Časový rámec sdílení IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Kritéria přístupu pro sdílení IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ICF
- CSR
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .